Literature DB >> 22258607

The DNA damage response and cancer therapy.

Christopher J Lord1, Alan Ashworth.   

Abstract

Genomic instability is one of the most pervasive characteristics of tumour cells and is probably the combined effect of DNA damage, tumour-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells. Although these processes drive genomic instability and ultimately the disease process, they also provide therapeutic opportunities. A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258607     DOI: 10.1038/nature10760

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  72 in total

Review 1.  Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity.

Authors:  James E Cleaver; Ernest T Lam; Ingrid Revet
Journal:  Nat Rev Genet       Date:  2009-10-07       Impact factor: 53.242

2.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

Authors:  J Chad Brenner; Bushra Ateeq; Yong Li; Anastasia K Yocum; Qi Cao; Irfan A Asangani; Sonam Patel; Xiaoju Wang; Hallie Liang; Jindan Yu; Nallasivam Palanisamy; Javed Siddiqui; Wei Yan; Xuhong Cao; Rohit Mehra; Aaron Sabolch; Venkatesha Basrur; Robert J Lonigro; Jun Yang; Scott A Tomlins; Christopher A Maher; Kojo S J Elenitoba-Johnson; Maha Hussain; Nora M Navone; Kenneth J Pienta; Sooryanarayana Varambally; Felix Y Feng; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

3.  NHEJ and its backup pathways in chromosomal translocations.

Authors:  Michael R Lieber
Journal:  Nat Struct Mol Biol       Date:  2010-04       Impact factor: 15.369

4.  Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster.

Authors:  J C Lucchesi
Journal:  Genetics       Date:  1968-05       Impact factor: 4.562

Review 5.  Integrating genetic approaches into the discovery of anticancer drugs.

Authors:  L H Hartwell; P Szankasi; C J Roberts; A W Murray; S H Friend
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

6.  Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.

Authors:  Wataru Sakai; Elizabeth M Swisher; Céline Jacquemont; Kurapaty Venkatapoorna Chandramohan; Fergus J Couch; Simon P Langdon; Kaitlyn Wurz; Jake Higgins; Emily Villegas; Toshiyasu Taniguchi
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

7.  Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture.

Authors:  J Mendeleyev; E Kirsten; A Hakam; K G Buki; E Kun
Journal:  Biochem Pharmacol       Date:  1995-08-25       Impact factor: 5.858

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 9.  Making the best of PARP inhibitors in ovarian cancer.

Authors:  Susana Banerjee; Stan B Kaye; Alan Ashworth
Journal:  Nat Rev Clin Oncol       Date:  2010-08-10       Impact factor: 66.675

10.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

View more
  580 in total

1.  PARP pairs up to PARsylate.

Authors:  Nicolas Coquelle; J N Mark Glover
Journal:  Nat Struct Mol Biol       Date:  2012-07-05       Impact factor: 15.369

Review 2.  Functional assays for analysis of variants of uncertain significance in BRCA2.

Authors:  Lucia Guidugli; Aura Carreira; Sandrine M Caputo; Asa Ehlen; Alvaro Galli; Alvaro N A Monteiro; Susan L Neuhausen; Thomas V O Hansen; Fergus J Couch; Maaike P G Vreeswijk
Journal:  Hum Mutat       Date:  2013-12-03       Impact factor: 4.878

3.  The histone variant macroH2A1.1 is recruited to DSBs through a mechanism involving PARP1.

Authors:  Chang Xu; Ye Xu; Ozge Gursoy-Yuzugullu; Brendan D Price
Journal:  FEBS Lett       Date:  2012-09-29       Impact factor: 4.124

4.  ATR Plays a Direct Antiapoptotic Role at Mitochondria, which Is Regulated by Prolyl Isomerase Pin1.

Authors:  Benjamin A Hilton; Zhengke Li; Phillip R Musich; Hui Wang; Brian M Cartwright; Moises Serrano; Xiao Zhen Zhou; Kun Ping Lu; Yue Zou
Journal:  Mol Cell       Date:  2015-09-18       Impact factor: 17.970

Review 5.  DNA damage and tissue repair: What we can learn from planaria.

Authors:  Paul G Barghouth; Manish Thiruvalluvan; Melanie LeGro; Néstor J Oviedo
Journal:  Semin Cell Dev Biol       Date:  2018-05-03       Impact factor: 7.727

Review 6.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

7.  Restoration of ASC expression sensitizes colorectal cancer cells to genotoxic stress-induced caspase-independent cell death.

Authors:  Sujeong Hong; Inhwa Hwang; Yun-Sun Lee; Sangjun Park; Won-Keun Lee; Teresa Fernandes-Alnemri; Emad S Alnemri; You-Sun Kim; Je-Wook Yu
Journal:  Cancer Lett       Date:  2013-01-12       Impact factor: 8.679

Review 8.  PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?

Authors:  Michelle Lightfoot; Lauren Montemorano; Kristin Bixel
Journal:  Curr Oncol Rep       Date:  2020-02-17       Impact factor: 5.075

9.  TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.

Authors:  Yang Peng; Hui Dai; Edward Wang; Curtis Chun-Jen Lin; Wei Mo; Guang Peng; Shiaw-Yih Lin
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

10.  Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer.

Authors:  Rui-Lei Liu; Ye Dong; Yan-Zhen Deng; Wen-Jun Wang; Wei-Dong Li
Journal:  Tumour Biol       Date:  2015-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.